Aavas Financiers Fund Raise of ₹630 Cr

Aavas Financiers Debt & Borrowing: ₹22.3 Cr

Aavas Financiers certified timely half-yearly interest payment of ₹22.30 Crore on its NCDs (ISIN INE216P07241). No redemption payment was made during the period.

Value

₹22.30 Cr

Aavas Financiers Regulatory Approval

AAVAS Financiers received an IRDAI Certificate of Registration to act as a Corporate Agent, effective December 8, 2026, and perpetual subject to annual fees. The approval lets the company solicit insurance products to its customers.

Execution

Valid from December 08, 2026; perpetual subject to annual fee and compliance

Aavas Financiers Management Change

AAVAS Financiers accepted the resignation of Independent Director Soumya Rajan and HIA Ramachandran Venkatesh, and appointed Anjali Seth as Independent Director and Bharat Thakkar as HIA. A postal ballot for Seth's appointment was also approved.

Aavas Financiers Results Update

AAVAS Financiers released H1FY27 investor highlights, with net profit up 16.4% YoY to ₹3.5 billion. Figures come from a press release, not a full results statement.

Aavas Financiers Investor Presentation: Key Takeaways

H1FY27 PAT ₹3,528mn (+16.4% YoY); Q2FY27 PAT ₹1,815mn (+10.7% YoY). AUM ₹248bn (+16%), Q2 NIM 7.81%. Focus on 20% AUM growth.

Aavas Financiers Q2 FY27 Results: Net Profit ₹181.5 Cr, Up 10.7% YoY

Aavas Financiers Ltd reported revenue from operations of ₹736.3 Cr (+10.4% YoY) and net profit of ₹181.5 Cr (+10.7% YoY) for Q2 FY27.

Key figure

Net profit ₹181.5 Cr · +10.7% YoY

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr